Skip to main content
Full access
Letter to the Editor
Published Online: 1 April 2002

Nerve Growth Factor and Smoking Cessation

Publication: American Journal of Psychiatry
To the Editor: Nerve growth factor is the best characterized neurotrophin essential for neuron survival, differentiation, and function in the peripheral and central nervous systems (1). In addition, it is hypothesized that nerve growth factor plays a modulatory role in the immune system, is involved in the regulation of specific neuroendocrine functions, and is elevated in psychologically stressful situations (1). Because acute nicotine withdrawal is associated with psychological stress, and an elevation of nerve growth factor has been shown to also accompany alcohol withdrawal (2), we hypothesized that the level of nerve growth factor is elevated during withdrawal from smoking.
We studied eight female and seven male smokers (mean age=35.0 years, SD=10.7) and 10 matched pairs of nonsmokers. All of the subjects gave their written informed consent. The smokers had consumed more than 10 cigarettes a day for 5 or more years and had been medication free within the past year. Having any psychiatric or medical disorder led to exclusion from the study. Their grade of nicotine dependence was measured with the Fagerstrom Tolerance Questionnaire (3). Serum concentrations of nerve growth factor were measured in smokers on 3 consecutive days at the same time of day (within 15 minutes) and once in nonsmokers. On days 1 and 3, the smokers consumed at least eight cigarettes before blood was drawn; on day 2 they were abstinent for 16 hours or more. Measurement on day 3 was performed to detect delayed changes in nerve growth factor level.
No significant difference was detected in baseline levels of nerve growth factor between the smokers (mean=63.4 pg/ml, SD=117.8) and the nonsmokers (mean=57.3 pg/ml, SD=96.6) (Mann-Whitney-Wilcoxon S=137.0, df=14, exact p=0.71). Our main finding was a significant overall change in nerve growth factor levels in the smokers over the 3 days observed (Friedman S=7.56, df=2, exact p=0.02). Post hoc analysis revealed a significant increase in nerve growth factor levels between day 2 (mean=76.3 pg/ml, SD=176.3) and day 3 (mean=104.5 pg/ml, SD=266.4) (Wilcoxon S=39.50, df=14, exact p=0.03, with Bonferroni correction). Fagerstrom score was positively correlated with nerve growth factor level at baseline (Spearman’s r=0.53, df=13, p=0.04) but not with change in nerve growth factor level.
In line with this observation, a release of nerve growth factor into the bloodstream was found in adult male mice in social isolation as well as in parachutists experiencing their first jump, suggesting that psychological stress is associated with an increase in serum level of nerve growth factor (1). Moreover, high levels of serum nerve growth factor in patients during acute withdrawal from alcohol or heroine addiction (2) indicate involvement of nerve growth factor in addictive behavior and withdrawal distress. The positive correlation found between Fagerstrom score and nerve growth factor concentration strengthens the possibility of a connection with addictive behavior. This study represents, to our knowledge, the first observation that the serum concentration of nerve growth factor is altered during acute withdrawal from nicotine, although this finding must be considered as preliminary and needs replication.

References

1.
Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A: Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19:514-520
2.
Aloe L, Tuveri MA, Guerra P, Pinna L, Tirassa P, Micera A, Alleva E: Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Alcohol Clin Exp Res 1996; 3:462-466
3.
Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF: Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. Addict Behav 1994; 19:33-39

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 674-a - 675

History

Published online: 1 April 2002
Published in print: April 2002

Authors

Affiliations

JÜRGEN GALLINAT, M.D.
MARIA C. JOCKERS-SCHERÜBL, M.D.
RAINER HELLWEG, M.D.
Berlin, Germany

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share